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The aim of this systematic review is to examine the eﬃcacy of Garcinia extract, hydroxycitric acid (HCA) as a weight reduction
agent, using data from randomised clinical trials (RCTs). Electronic and nonelectronic searches were conducted to identify relevant
articles, with no restrictions in language or time. Two independent reviewers extracted the data and assessed the methodological
quality of included studies. Twenty-three eligible trials were identified and twelve were included. Nine trials provided data suitable
for statistical pooling. The meta-analysis revealed a small, statistically significant diﬀerence in weight loss favouring HCA over
placebo (MD: −0.88 kg; 95% CI: −1.75, −0.00). Gastrointestinal adverse events were twice as common in the HCA group
compared with placebo in one included study. It is concluded that the RCTs suggest that Garcinia extracts/HCA can cause short-
term weight loss. The magnitude of the eﬀect is small, and the clinical relevance is uncertain. Future trials should be more rigorous
and better reported.
1. Introduction
The prevalence of overweight and obesity has increased over
the last decade [1], and current measures have not been
able to stem the tide. A wide variety of weight management
strategies are presently available, and some involve the use
of dietary supplements marketed as slimming aids. One
such slimming aid is Garcinia extract, (-)-hydroxycitric acid
(HCA).
HCA is a derivative of citric acid and can be found in
plant species native to South Asia such as Garcinia cambogia,
Garcinia indica, and Garcinia atroviridis [2]. HCA is usually
marketed as a weight loss supplement either alone or in
combination with other supplements [2, 3]. Some authors
have suggested that HCA causes weight loss by competitively
inhibiting the enzyme adenosine triphosphatase-citrate-lyase
[3–6]. HCA has also been reported to increase the release
or availability of serotonin in the brain, thereby leading to
appetite suppression [7]. Other postulated weight loss mech-
anisms include inhibition of pancreatic alpha amylase and
intestinal alpha glucosidase, thereby leading to a reduction
in carbohydrate metabolism [8].
Animal studies have suggested that HCA causes weight
loss [3, 9], and human trials involving the use of HCA as a
weight loss supplement have been carried out [3].
The primary objective of this systematic review was to
examine the eﬃcacy of HCA in reducing body weight in
humans, using data from randomised clinical trials.
2. Methods
Electronic searches of the literature were conducted in the
following databases: Medline, Embase, The Cochrane Library,
Amed, and Cinahl. The search terms used included dietary
supplements, antiobesity agents, body weight, hydroxyci-
trate, garcinia, and derivatives of these. Each database was
searched from inception until March, 2010. We also searched
the Internet for relevant conference proceedings and hand
searched relevant medical journals, and our own files. The
bibliographies of all located articles were also searched.
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•
11 articles excluded for the following reasons:
•HCA as part of a combination package: 6
• Unblinded trial: 1
• Single-blinded trial: 1
• Duplicates: 2
• Didn’t measure body weight: 1
12 randomised clinical
trials included
23 full texts/abstracts retrieved
for more detailed evaluation of
the articles
5002 references retrieved
4979 articles excluded based on title/abstract, mainly
because they did not investigate a food supplement for
weight loss or the study design was unsuitable
Figure 1: Flow chart showing the process for the inclusion of randomised controlled trials.
Only randomised, double-blind, placebo-controlled
studies were included in this paper. To be considered for
inclusion, studies had to test the eﬃcacy of oral HCA or
any of its salts for weight reduction in obese or overweight
humans. Included studies also had to report body weight
as an outcome. No age, time, or language restrictions were
imposed for inclusion of studies. Studies which involved
the use of HCA as part of a combination treatment (dietary
interventions containing other supplements in addition to
HCA), or not involving obese or overweight subjects based
on body mass index (BMI) values, were excluded from this
paper.
Two independent reviewers assessed the eligibility of
studies to be included in the paper. Data were extracted
systematically by two independent reviewers according to
the patient characteristics, interventions, and results. The
methodological quality of all included studies was assessed
by the use of a quality assessment checklist adapted from
the Consolidated Standard of Reporting Trials (CONSORT)
guidelines [10, 11]. In addition, the Jadad score [12] was also
used to assess the quality of included studies. Disagreements
were resolved through discussion with the other authors.
Data are presented as means with standard deviations.
Mean changes in body weight were used as common
endpoints to assess the diﬀerences betweenHCA and placebo
groups. Using the standard meta-analysis software [13], we
calculated mean diﬀerences (MDs) and 95% confidence
intervals (CIs). Studies included in the meta-analysis were
weighted by SD (a proxy for study size). If a trial had 3
arms, only the HCA and placebo arms were included in the
meta-analysis. The I2 statistic was used to assess for statistical
heterogeneity amongst studies. A funnel plot was used to test
for publication bias.
3. Results
Our searches produced 5002 “hits” of which 23 potentially
relevant articles were identified (Figure 1). Six trials were
excluded because they involved the use of HCA in combina-
tion with other therapies [7, 14–18]. One trial was excluded
because it was not blinded [19], and another because it
was single blinded [20]. Two articles were excluded because
they were duplicates. One of these articles [21] was the
same trial published in another journal which had been
earlier excluded, while the other article [22] was a report of
two individual trials which were included in this systematic
review. One trial was excluded because the investigators did
not measure weight as an outcome [23]. Thus 12 randomised
clinical trials (RCTs) including a total of 706 participants met
our inclusion criteria, and were included in this systematic
review [2, 4–6, 24–31]. Their key details are summarized in
Tables 1, 2, and 3.
All of the studies had one or more methodological
weaknesses (Table 1). None of the included studies reported
on how double blinding was carried out, and all studies
were also unclear about how the allocation was concealed.
The randomization procedure was clear in only a third of
included studies [4, 6, 25, 29].
Three RCTs [4, 28, 31] did not provide actual values
to enable statistical pooling (Table 3). One of these RCTs
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Table 3: Results of included studies without suitable data for meta-analysis.ρ
Author
Year
Country
HCA
formulation
Randomised/
Analysed
Age in yrs
HCA
Dosage
Treatment
Duration
Baseline weight
indices for
HCA/placebo
groups
Main Results
Adverse
events
(AE)
Control
for lifestyle
factors
Hayamizu
et al. 2003
Japan [4]
Tablets 44/39
43.7± 11.9
(HCA)
45.2± 13.0
(PLA)
1 g daily 12 weeks
BW:
75.1± 12.3/
75.9± 11.5
BMI:
28.9± 4.7/
28.5± 4.6
No significant
diﬀerences in
BMI or body
weight at week 12
Common
cold,
toothache,
diarrhea
Dietary
control
Preuss et al.
2002
(abstract)
India [28]
Unspecified 48/unclear
Not
reported
2.8 g daily 8 weeks Not reported
4.8% loss in body
weight, and 6.8%
decrease in BMI
for HCA group
Not
reported
Diet
control,
exercise
Thom 1996
(abstract)
Norway
[31]
Capsule 60/unclear
Not
reported
1.32 g daily 8 weeks Not reported
Significant
decrease in body
weight in HCA
group compared
with placebo
(P < .001)
Stomach
ache
Low fat
diet,
exercise
Abbreviations: HCA: Hydroxycitric acid; PLA: Placebo; BW: Body Weight; BMI: Body Mass Index.
ρUnless otherwise stated, all trials are parallel-study designs.
reported a nonsignificant diﬀerence in BMI or body weight
between groups [4], another reported a significant diﬀerence
(P < .001) in the HCA group compared with placebo [31].
The third RCT [28] reported a decrease in body weight and
(BMI) from baseline for the HCA group, without providing
results of intergroup diﬀerences.
A forest plot (random eﬀect model) for studies with
data suitable for statistical pooling is shown in Figure 2. The
meta-analysis reveals a statistically significant diﬀerence in
body weight between the HCA and placebo groups. The
average eﬀect size was, however, small (MD: −0.88 kg; 95%
CI: −1.75, −0.00), with a P value of .05. This translates to
about 1% in body weight loss in HCA group compared with
placebo. The I2 statistic suggests that there was considerable
heterogeneity amongst the trials, the duration of treatment,
and the dosages of HCA used in the diﬀerent trials varied
widely. A funnel plot of mean diﬀerence plotted against trial
sample size (Figure 3) indicated that most of the studies
(which had small sample sizes) were distributed around the
mean diﬀerence of all the trials.
Sensitivity analyses were performed to test the robustness
of the overall analysis. The first included 7 trials [2, 5, 6,
24, 25, 29, 30] with parallel-group design, excluding two
studies which were crossover [26, 27]. Meta-analysis of these
trials revealed MD of −1.22 kg (95% CI: −2.29, −0.14).
Heterogeneity was substantial. A second meta-analysis for
studies with parallel group designs and dosage ranges of
HCA between 1 and 1.5 g per day [5, 24, 25, 30] did not
reveal a significant diﬀerence between HCA and placebo;
heterogeneity was also substantial in this analysis. A third
meta-analysis excluding three studies with outlying data for
MD [6, 29, 30] did not reveal a significant diﬀerence in
weight loss between HCA and placebo, but heterogeneity
was considerable. A further meta-analysis of the two trials
with good methodological quality [6, 25] revealed a non-
significant diﬀerence in weight loss (MD: 0.88 kg; 95% CI:
−0.33, 2.10) between HCA and placebo, with I2 value of
0, suggesting that heterogeneity might not be important.
Finally, a meta-analysis of the change in BMI for four studies
[6, 24, 29, 31] did not reveal any significant diﬀerence
between HCA and placebo (MD: −0.34 kg; 95% CI: −0.88,
0.20), with I2 value of 0.
One study [2] reported a significant decrease in fat mass
in the HCA group compared with placebo (P < .05),
while two studies [4, 24] reported a significant decrease in
visceral, subcutaneous, and total fat areas in the HCA group
compared with placebo (P < .001). In contrast two other
studies [5, 25] found no significant diﬀerence in body fat loss
between HCA and placebo.
Adverse events reported in the RCTs included headache,
skin rash, common cold, and gastrointestinal (GI) symp-
toms. In most of the studies, there were no major diﬀerences
in adverse events between the HCA and placebo groups.
However, in one trial, GI adverse events were twice as
frequent in the HCA group compared with the placebo
group [25]. In total, there were 88 drop outs. A further 45
participants were reported to have been excluded from the
analysis in one trial [5] because they either took a mixture of
HCA and placebo (28), or were males (17).
4. Discussion
The objective of this systematic review was to assess the
eﬃcacy and eﬀectiveness of HCA as a weight reduction
agent. The overall meta-analysis revealed a small diﬀerence
in change in body weight between the HCA and placebo
groups. The eﬀect is of borderline statistical significance and
is no longer significant on the basis of a sensitivity analysis
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Figure 2: Forest plot of comparison showing the eﬀect of hydroxycitrate on body weight. The vertical line represents no diﬀerence in weight
loss between HCA and placebo.
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Figure 3: Funnel plot of the mean diﬀerence in body weight
reduction trials of HCA, plotted against sample size. The vertical
line depicts the weighted mean diﬀerence of all trials.
of rigorous RCTs. Arguably the overall eﬀect size is also too
small to be of clinical relevance. The overall meta-analytic
result corroborates the findings from one of the studies
without suitable data for statistical pooling [31], but is at
variance with another study [4].
The overall result should be interpreted with caution.
The pooled data from some of the studies were adjusted
values. Three studies with small sample sizes [6, 29, 30]
seemed to have influenced the overall meta-analytic result in
favour of HCA over placebo. If these three trials are excluded,
the meta-analysis result is no longer significant. The largest
and most rigorous RCT [25] found no significant diﬀerence
in weight loss between HCA and placebo.
The result of our systematic review corroborates the
findings from a previous systematic review of weight loss
supplements, which reported that the weight reducing eﬀects
of most dietary supplements is not convincing [32]. HCA
is a commonly marketed as a complementary weight loss
supplement. The meta-analysis from this systematic review
suggests that HCA is not as eﬀective as conventional weight
loss pills, for example, orlistat. In a meta-analysis report of 16
studies including over 10 000 participants [33], overweight
and obese patients taking orlistat had a clinically significant
reduction in body weight compared to placebo (MD: 2.9 kg;
95% CI: 2.5, 3.2). Participants taking orlistat achieved a 5%
and 10% weight loss compared to placebo in the results from
pooled data. This contrasts quite sharply with the results
from the meta-analysis of HCA clinical trials.
All of the studies included in this review had method-
ological issues, which are likely to have aﬀected the outcomes
in these trials. This is supported by the I2 values from
the overall meta-analysis result which suggested substantial
heterogeneity. Most of the studies included in this systematic
review had small sample sizes. Only one included study [25]
reported that they performed a power calculation. Larger
study sizes with a priori sample size calculation will help
eliminate a type II error (i.e., failure to reject the null
hypothesis when it should have been rejected). Only one
study [25] performed an intention to treat (ITT) analysis,
while all the participants in three other studies [24, 26, 27]
were reported to have completed the trial. The failure of
about 66% of the included studies to report ITT analyses
casts a doubt as to the validity of their results. In several of
the RCTs, drop-outs/attrition was unclear. In one study [5],
participants were excluded due to mixed-pill ingestion (an
error in coding of pill bottles resulted in some participants
receiving a mixture of HCA and placebo). Male participants
were also excluded from the analysis of this RCT because they
were too few in number compared with females in the trial.
It was also unclear to which intervention group the excluded
participants belonged to in this study.
The dosage of HCA, and the duration of study also varied
amongst the RCTs. The dosage of HCA used ranged from
1 g to 2.8 g daily. The optimal dose of HCA is currently
unknown. Two included studies which diﬀered widely in
results [25, 29] also diﬀered widely in dosage of HCA.
Journal of Obesity 7
Dose eﬀect of HCA on body weight
0.5
−0.9
−0.1
0.5
1.3
2.9
4.1
2.8
−2
−1
0
1
2
3
4
5
0 0.5 1 1.5 2 2.5 3
Dosage (g)
W
ei
gh
t
lo
ss
(k
g)
Figure 4: Eﬀect of dosage of HCA on body weight. The dosages
from included RCTs did not produce a linear eﬀect on body weight.
Though one of these studies claimed the bioavailability of
the HCA used in their trial was high [25], the dosage of
HCA used was almost twice that used in the other trial [29].
It is not clear if the higher HCA dosage ensures a higher
bioavailability of HCA. A nonlinear, significant (P < .05)
correlation between the dosage of HCA and body weight loss
seems to exist (Figure 4). Garcinia cambogia was the main
source of HCA in most studies, with Garcinia atroviridis
being the source of HCA in one included study [2]. None of
the trials used Garcinia indica as an intervention. It is unclear
if the strain of Garcinia species influences the bioavailability
of HCA. Furthermore HCA is also reported to be found in
Hibiscus subdariﬀa [8], and none of the studies included in
this review used HCA extracted from this plant species. The
duration of the studies included in the review also diﬀered,
with a range of 2 to 12 weeks, and mode of 8 weeks. This
is probably too short a time to assess the eﬀects of HCA on
body weight.
There was some variation in the design of the RCTs
included in the review. All of the studies included had
parallel-study designs except two which were crossover trials
[26, 27]. Four included RCTs comprised three intervention
groups [6, 26, 27, 29]. None of the included studies indicated
whether or not outcome assessors were blinded, and seven
studies did not specify the source of funding [2, 4, 6, 24, 28,
29, 31]. The failure of study investigators to adhere strictly
to the CONSORT guidelines [10, 11] may have contributed
to the variation in methodology (and heterogeneity) of the
trials included in the review.
Most (7/12) RCTs reported adverse events, with
headache, nausea, upper respiratory, and gastrointestinal
tract symptoms being the most frequent ones. In most of the
trials, there were no significant diﬀerences in adverse events
between HCA and placebo. This seems to corroborate the
report in another article [34] which suggested that HCA is
safe for human consumption. A few of the studies reported a
positive eﬀect of HCA on the blood lipid profile [6, 24, 29–
31], while one did not find any significant diﬀerence between
HCA and placebo on this blood parameter [2]. However,
given the short duration of the studies involving the use
of HCA, it is unclear how safe this dietary supplement is
on the intermediate and long term. In 2009, the Food and
Drug Administration (FDA) warned consumers about the
potential for serious adverse eﬀects associated with the
consumption of hydroxycut, a popular HCA-containing
slimming pill. This resulted in the withdrawal of this
supplement from the market [35].
All of the studies included in this review except two
[26, 27] incorporated some form of dietary control into their
trials, with participants in one study receiving high fibre diets
[25]. The daily caloric intake for participants in the trials
included in this review ranged from as low as 1,000 kcal
[2, 30], to as high as 3,009 kcal [27]. Half the number of
studies in this review did not institute any form of exercise.
The extent to which the variation in these lifestyle adjustment
factors could have influenced study results is uncertain. Two
studies [28, 31] reported a significant reduction in appetite
in the HCA group (P < .001), but not with placebo. Three
other studies did not find any significant diﬀerence between
HCA and placebo groups in terms of satiety eﬀect [5, 26, 27].
All of the studies described their participants as over-
weight, obese, or both. However, in one RCT [2], the
definition of the participants as obese individuals is ques-
tionable, because they had a BMI between 25–30 kg/m2.
Based on the World Health Organisation definition [36], a
BMI between 25–29 kg/m2 is considered overweight, while a
BMI ≥ 30 kg/m2 is termed obese.
This systematic review has several limitations. Though
our search strategy involved both electronic and non-
electronic studies, wemay not have identified all the available
trials involving the use of HCA as a weight loss supplement.
Furthermore, the methodological quality of most of the
studies identified from our searches is poor, and most studies
are of short duration. These factors prevent us from drawing
firm conclusions about the eﬀects of HCA on body weight.
5. Conclusion
The evidence fromRCTs suggests thatGarcinia extracts/HCA
generate weight loss on the short term. However, the
magnitude of this eﬀect is small, is no longer statistically
significant when only rigorous RCTs are considered, and its
clinical relevance seems questionable. Future trials should be
more rigorous, longer in duration, and better reported.
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